exRNAdisease

Entry Detail

---



General Information

Database ID: exR0088036 RNA Name: hsa-miR-3118 RNA Type: miRNA Chromosome: chr15 Starnd: + Coordinate: Start Site(bp): 21843793 End Site(bp): 21843815 External Links: hsa-miR-3118

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: NA miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000642 chr15 80390757 80415142 + hsa_circ_0000643 chr15 80412669 80415142 + hsa_circ_0000798 chr17 65941524 65944422 + hsa_circ_0000799 chr17 65941524 65972074 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC004687.1 chr17 58330884 58332508 - AC009948.3 chr2 178541125 178541799 + AC092127.1 chr16 85592266 85595720 + AC097634.1 chr3 71584943 71587409 + AC144548.1 chr12 110387463 110445548 - AC145207.5 chr17 81878425 81881106 - ADAMTSL4-AS1 chr1 150560202 150574552 - DNM3OS chr1 172138397 172144840 - ENTPD3-AS1 chr3 40313802 40453329 - KCNQ1OT1 chr11 2608328 2699994 - LINC01278 chrX 63222993 63561095 - NEAT1 chr11 65422774 65445540 + PINK1-AS chr1 20642657 20652193 - TDRKH-AS1 chr1 151790804 151794402 + Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.